Comparative effects of high and low-dose simvastatin on prostate epithelial cells: The role of LDL

European Journal of Pharmacology

Volumn 673, Issue 1-3, 2011, Pages 96-100

  Murtola, Teemu J ^a,b   Syvälä, Heimo ^a   Pennanen, Pasi ^a   Bläuer, Merja ^c   Solakivi, Tiina ^a   Ylikomi, Timo ^a   Tammela, Teuvo L J ^a,c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b Central Finland Central Hospital   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cell cycle; Cell proliferation; Epithelial cell; Low density lipoprotein; Prostate; Simvastatin

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; ROSUVASTATIN; SIMVASTATIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; HYDROPHOBICITY; LIPOPHILICITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; SENESCENCE;

APOPTOSIS; CELL AGING; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEVALONIC ACID; PROSTATE; PROSTATIC NEOPLASMS; PYRIMIDINES; SIMVASTATIN; SULFONAMIDES;

EID: 81855207294     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.10.022     Document Type: Article

References (32)

1. J.M. Backes, P.A. Howard, J.F. Ruisinger, and P.M. Moriarty Does simvastatin cause more myotoxicity compared with other statins? Ann. Pharmacother. 43 2009 2012 2020
2. R.H. Breau, R.J. Karnes, D.J. Jacobson, M.E. McGree, S.J. Jacobsen, A. Nehra, M.M. Lieber, and J.L. St Sauver The association between statin use and the diagnosis of prostate cancer in a population based cohort J. Urol. 184 2010 494 499
3. M.S. Brown, and J.L. Goldstein Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth J. Lipid Res. 21 1980 505 517 (Pubitemid 11194847)
4. P.R. Dillard, M.F. Lin, and S.A. Khan Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol Mol. Cell. Endocrinol. 295 2008 115 120
5. E.D. Flick, L.A. Habel, K.A. Chan, S.K. Van Den Eeden, V.P. Quinn, R. Haque, E.J. Orav, J.D. Seeger, M.C. Sadler, C.P. Quesenberry Jr., B. Sternfeld, S.J. Jacobsen, R.A. Whitmer, and B.J. Caan Statin use and risk of prostate cancer in the California Men's Health Study cohort Cancer Epidemiol. Biomarkers Prev. 16 2007 2218 2225 (Pubitemid 351196352)
6. G.D. Friedman, E.D. Flick, N. Udaltsova, J. Chan, C.P. Quesenberry Jr., and L.A. Habel Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients Pharmacoepidemiol. Drug Saf. 17 2008 27 36 (Pubitemid 351166615)
7. J.L. Goldstein, and M.S. Brown Regulation of the mevalonate pathway Nature 343 1990 425 430
8. R. Gutt, N. Tonlaar, R. Kunnavakkam, T. Karrison, R.R. Weichselbaum, and S.L. Liauw Statin use and risk of prostate cancer recurrence in men treated with radiation therapy J. Clin. Oncol. 28 2010 2653 2659
9. R.J. Hamilton, L.L. Banez, W.J. Aronson, M.K. Terris, E.A. Platz, C.J. Kane, J.C. Presti Jr., C.L. Amling, and S.J. Freedland Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database Cancer 116 2010 3389 3398
10. A. Hoque, H. Chen, and X.C. Xu Statin induces apoptosis and cell growth arrest in prostate cancer cells Cancer Epidemiol. Biomarkers Prev. 17 2008 88 94 (Pubitemid 351196277)
11. O. Jaakkola, O.P. Kallioniemi, and T. Nikkari Lipoprotein uptake in primary cell cultures of rabbit atherosclerotic lesions, a fluorescence microscopic and flow cytometric study Atherosclerosis 69 1988 257 268 (Pubitemid 18018620)
12. E.J. Jacobs, C. Rodriguez, E.B. Bain, Y. Wang, M.J. Thun, and E.E. Calle Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort Cancer Epidemiol. Biomarkers Prev. 16 2007 2213 2217 (Pubitemid 351196351)
13. M.A. Kollmeier, M.S. Katz, K. Mak, Y. Yamada, D.J. Feder, Z. Zhang, X. Jia, W. Shi, and M.J. Zelefsky Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy Int. J. Radiat. Oncol. Biol. Phys. 79 2011 713 718
14. J.R. Krycer, I. Kristiana, and A.J. Brown Cholesterol homeostasis in two commonly used human prostate cancer cell-lines, LNCaP and PC-3 PLoS One 4 2009 e8496
15. W. Kueng, E. Silber, and U. Eppenberger Quantification of cells cultured on 96-well plates Anal. Biochem. 182 1989 16 19 (Pubitemid 19251274)
16. J. Lee, I. Lee, C. Park, and W.K. Kang Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells Biochem. Biophys. Res. Commun. 339 2006 748 754 (Pubitemid 41772877)
17. J. Martinez-Botas, A.J. Ferruelo, Y. Suarez, C. Fernandez, D. Gomez-Coronado, and M.A. Lasuncion Dose-dependent effects of lovastatin on cell cycle progression, distinct requirement of cholesterol and non-sterol mevalonate derivatives Biochim. Biophys. Acta 1532 2001 185 194 (Pubitemid 32706438)
18. F. McTaggart Comparative pharmacology of rosuvastatin Atheroscler. Suppl. 4 2003 9 14 (Pubitemid 38234502)
19. I.W. Mills, A. Crossland, A. Patel, and H. Ramonas Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement Eur. Urol. 52 2007 503 509 (Pubitemid 46963443)
20. T.J. Murtola, P. Pennanen, H. Syvala, M. Blauer, T. Ylikomi, and T.L. Tammela Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations Prostate 69 2009 1017 1023
21. T.J. Murtola, T.L. Tammela, J. Lahtela, and A. Auvinen Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study Cancer Epidemiol. Biomarkers Prev. 16 2007 2226 2232 (Pubitemid 351196353)
22. T.J. Murtola, T. Visakorpi, J. Lahtela, H. Syvälä, and T.L.J. Tammela Statins and prostate cancer prevention: where are we now and future directions Nat. Clin. Pract. Urol. 5 2008 376 387
23. H.Y. Pan, A.R. DeVault, D. Wang-Iverson, E. Ivashkiv, B.N. Swanson, and A.A. Sugerman Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin J. Clin. Pharmacol. 30 1990 1128 1135
24. T.S. Parker, D.J. McNamara, C. Brown, O. Garrigan, R. Kolb, H. Batwin, and E.H. Ahrens Jr. Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man Proc. Natl. Acad. Sci. U. S. A. 79 1982 3037 3041 (Pubitemid 12058612)
25. S.K. Patra Dissecting lipid raft facilitated cell signaling pathways in cancer Biochim. Biophys. Acta 1785 2008 182 206
26. E.A. Platz, M.F. Leitzmann, K. Visvanathan, E.B. Rimm, M.J. Stampfer, W.C. Willett, and E. Giovannucci Statin drugs and risk of advanced prostate cancer J. Natl. Cancer Inst. 98 2006 1819 1825 (Pubitemid 46017933)
27. U. Sivaprasad, T. Abbas, and A. Dutta Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells Mol. Cancer Ther. 5 2006 2310 2316 (Pubitemid 44530468)
28. K.R. Solomon, and M.R. Freeman Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol. Metab. 19 2008 113 121 (Pubitemid 351608305)
29. M.R. Soma, A. Corsini, and R. Paoletti Cholesterol and mevalonic acid modulation in cell metabolism and multiplication Toxicol. Lett. 1.15 1992 64 65
30. C. Stancu, and A. Sima Statins: mechanism of action and effects J. Cell. Mol. Med. 5 2001 378 387
31. J.L. St Sauver, S.J. Jacobsen, D.J. Jacobson, M.E. McGree, C.J. Girman, A. Nehra, V.L. Roger, and M.M. Lieber Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms BJU Int. 107 2011 443 450
32. A.S. Wierzbicki, R. Poston, and A. Ferro The lipid and non-lipid effects of statins Pharmacol. Ther. 99 2003 95 112 (Pubitemid 36694752)